Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 10/05/2024 BST			5-day change	1st Jan Change
3.15 ^USD	+5.00%		+6.60%	-5.97%

05-07	Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-05	Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 09, 2022 at 09:05 pm

Cyclerion Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 0.306 million compared to USD 3 million a year ago. Net loss was USD 13.39 million compared to USD 16.18 million a year ago. Basic loss per share from continuing operations was USD 6.2 compared to USD 9 a year ago.
For the six months, revenue was USD 1.02 million compared to USD 3.06 million a year ago. Net loss was USD 26.37 million compared to USD 29.58 million a year ago. Basic loss per share from continuing operations was USD 12.2 compared to USD 17 a year ago.

Latest news about Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Cyclerion Therapeutics, Inc. Appoints Regina Graul as President	12-04	CI
Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments	11-30	CI
Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director	11-24	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer	23/10/23	CI
Cyclerion Therapeutics Acquires 10% Stake in Tisento Therapeutics in Asset Purchase Deal	31/07/23	MT
Tisento Therapeutics, Inc. announced that it has received $81 million in funding from Cyclerion Therapeutics, Inc., Invus, Polaris, and other investors	30/07/23	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/07/23	CI
Cyclerion Therapeutics, Inc. Announces Resignation of Cheryl Gault as Chief Operating Officer	27/06/23	CI
Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding	24/05/23	CI
Cyclerion Therapeutics to Implement 1-for-20 Reverse Stock Split	15/05/23	MT
Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Cyclerion Therapeutics to Sell Zagociguat, CY3018 Assets to New Private Company	12/05/23	MT
J & W Cycles, Inc. signed a definitive agreement to acquire sGC Stimulator Assets of Cyclerion Therapeutics, Inc. for $8 million.	10/05/23	CI
Cyclerion in Talks on Buyout Proposal for Drug Assets; CEO Offers to Make Equity Investment	03/04/23	MT
Cyclerion Therapeutics, Inc. announced that it expects to receive $5.000001 million in funding	30/03/23	CI
Cyclerion Therapeutics Says FDA Grants Orphan Drug Designation to Zagociguat; Shares Jump	27/03/23	MT
Cyclerion Gets FDA Orphan Designation for Zagociguat in Mitochondrial Diseases	27/03/23	DJ
Cyclerion Therapeutics' Zagociguat Gets FDA Orphan Drug Status	23/03/23	MT
Cyclerion Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	21/03/23	CI
North American Morning Briefing : Futures Deep in -3-	15/03/23	DJ
A group including Cyclerion Therapeutics, Inc.'s Chief Executive Officer cancelled the acquisition of Certain Assets of Cyclerion Therapeutics, Inc..	21/11/22	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/11/22	CI

Chart Cyclerion Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Companyâs portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
CYCLERION THERAPEUTICS, INC.	-5.97%	8M
MODERNA, INC.	+26.37%	44.96B
IQVIA HOLDINGS INC.	-1.01%	42.65B
LONZA GROUP AG	+46.00%	41.85B
CELLTRION, INC.	-5.31%	29.04B
ICON PUBLIC LIMITED COMPANY	+9.34%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	19.03B
BIO-TECHNE CORPORATION	+6.23%	12.75B
MEDPACE HOLDINGS, INC.	+26.99%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.75B

Other Biotechnology & Medical Research